Replies to post #753998 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

lol
It's quite amazing really

[SkyLimit2022]

ex,

I agree—sticky! 😉

Yes, for nGBM or rGBM, RANO would be appropriate…

Today, we have three versions of RANO and we should expect trials to reference elements of more than one of these criteria sets depending on the particular study agents:

1. RANO (‘old school’ conventional RANO)
2. mRANO (modified)
3. ⭐️iRANO (immunotherapy)

The DCVax-L P3 trial did not use iRANO criteria—it relied on conventional RANO guidelines. iRANO was developed to address immunotherapy challenges like pseudoprogression, and is now being used in ongoing trials (such as the DCVax-L pembrolizumab combo) to improve response assessment accuracy.

https://www.vjoncology.com/video/uj8-u2t1yee-comparison-of-response-assessment-criteria-in-glioblastoma-rano-mrano-and-irano/

iRANO’s refined methodology better distinguishes immune-related pseudoprogression from true tumor growth and enhances the accuracy of response assessments compared to earlier trials that used conventional RANO criteria.

As I mentioned, consider the example of the ongoing combo at UCLA for rGBM. This study is a combo with Merck’s pembrolizumab and RANO/iRANO is appropriately built into its design:

https://www.clinicaltrials.gov/study/NCT04201873